medigraphic.com
Colegio de Medicina Interna de México.

2013, Number 1

<< Back Next >>

Med Int Mex 2013; 29 (1)

IgG4 related disease

Carrillo ER, Echeverría VJA

Language: Spanish
References: 57
Page: 53-61
PDF size: 193.09 Kb.


ABSTRACT

IgG4-Related disease is a new disease characterized by inflammatory fibrosis with or without elevated serum IgG4. Clinically the disease may manifest with involvement of a single organ or multiple organs, this condition will be caused by the interaction between Th2 cells and B cells, which will produce high levels of IgG4 and inflammatory mediators that are expressed in tissues like lymphoplasmacytic infiltrates and fibrosis, however, apparently this is not the only mechanism involved in the pathophysiology of the disease. The assessment will require a combination of clinical, serological, histological and immunohistochemical characteristics, despite the lack of universal criteria for the diagnosis of the disease, experts have met to determine the key points needed to diagnose this disease. In general there has been good response to treatment with corticosteroids, however, alternative therapies are being tested if the patients have resistance to first-line therapy.


REFERENCES

  1. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, et al. A new clinicopathological entity of IgG4-related autoinmune disease. J Gastroenterol 2003;38:982-984.

  2. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-738.

  3. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012;22:1-14.

  4. Frulloni L, Lunardi C, Simone R, Dolcino M, Scattolini C, Falconi M, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009;361:2135-2142.

  5. Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009;104:2295-2306.

  6. Nishimori I, Tamakoshi A, Otsuki M. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. J Gastroenterol 2007; 42:Suppl 18:6-8.

  7. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002;105:9-19.

  8. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009 Apr; 39(4):469-477.

  9. Detlefsen S, Sipos B, Zhao J, Drewes AM, Kloppel G. Autoimmune pancreatitis: expression and cellular source of profibrotic cytokines and their receptors. Am J Surg Pathol 2008; 32:986-995.

  10. Lighaam L, Aalberse R, Rispens T. IgG4-Related Disease from an Immunological Perspective: Regulators out of Control? Int J Rheumatol 2012; 789164:1-6.

  11. Coelho V, Krysov S, Ghaemmaghami AM, et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenviromental lectins. Proceedings of the National Academy of Sciences of the United States of America 2011; 107(43):18587-18592.

  12. Kawa S, Ota M, Yoshizawa K, Horiuchi A, Ochi Y, Nakayama K, et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002; 122:1264-1269.

  13. Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology 2008; 134:440-446.

  14. K. Okazaki, K. Uchida, M. Koyabu, H. Miyoshi, and M. Takaoka. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterology 2011; 46(3):277-288.

  15. Guarneri F, Guarneri C, Benvenga S. Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry? J Cell Mod Med 2005; 9:741-744.

  16. Nishimori I, Tamaloshi A, Otsuki M, Research Committee on Intractable Diseases of the Pancreas, Ministry of Health, Labour, and Welfare of Japan. Prevalence of autoimmune pancreatitis in Japan from a natiowide survey in 2002. J Gastroenterol 2007; 42 Suppl 18:6.

  17. Deshpande V, Gupta R, Sainani NI, et al. Subclassification of Autoimmune pancreatitis: a histologic clasification with clinical significance. Am J Surg Pathol 2011; 35:26-35.

  18. Saeki T, Nishi S, Imai N, Ito T, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. N Engl J Med 2001; 344:732-738.

  19. Raissian Y, Nasr SH, Larsen CP, Fidler ME, et al. Significance of IgG4 immunostaining in plasma cell-rich tubulointerstitial nephritis. USCAP 2011, abstract #1484.

  20. Comings DE, Skubi KB, Van Eyes J, Motulsky AG. Familial multifocal fibrosclerosis. Ann Intern Med 1967; 66:884-892.

  21. Cheuk W, Tam FK, Chan AN, Luk IS, Yuen AP, Chan WK, et al. Idiopathic cervical fibrosis: a new member of IgG4 related sclerosing diseases – report of 4 cases, 1 complicated by composite lymphoma. Am J Surg Pathol 2010; 34:1678-1685.

  22. Roberts PF, McCann BG. Eosinophilic angiocentric fibrosis of the upper respiratory tract: a mucosal variant of granuloma faciale: - a report of three cases. Histopathology 1985; 9:1217-1225.

  23. Akram S, Pardi DS, Schaffner JA, Smyrk TC. Sclerosing mesenteritis: clinical features, treatment, and outcome in ninetytwo patients. Clin Gastroenterol Hepatol 2007; 5:589-596.

  24. Chen TS, Montgomery EA. Are tumefactive lesions classified as sclerosing mesenteritis a subset of IgG4 related sclerosing disorders? J Clin Pathol 2008; 61:1093-1097.

  25. Wallace ZS, Khosroshahi A, Jakobiec FA, Deshpande V, Hatton MP, Ritter J, et al. IgG4 related systemic disease as a cause of idiopathic orbital inflammation, including orbital myositis and trigeminal nerve involvement. Surv Ophtalmol 2011.

  26. Kubota T, Moritani S, Katayama M, Terasaki H. Ocular adnexal IgG4 related lymphoplasmacytic infiltrative disorder. Arch Ophthalmol 2010; 128:577-584.

  27. Cho HK, Lee YJ, Chung JH, Koo JW. Otologic manifestation in IgG4 related systemic disease. Clin Exp Otorhinolaryngol 2011; 4:52-54.

  28. Taniguchi T, Ko M, Seko S, Nishida O, Inoue F, Kobayashi H, et al. Interstitial pneumonia associated with autoimmune pancreatitis. Gut 2004; 53:770-774.

  29. Inoue D, Zen Y, Abo H, Gabata T, Demachi H, Kobayashi T, et al. Immunoglobulin G4-related lung disease: CT fidings with pathologic correlations. Radiology 2009; 251:260-270.

  30. Yoshimura Y, Takeda S, Ieki Y, Takazakura E, Koizumi H, Takagawa K. IgG4-associated prostatitis complicating autoinmune pancreatitis. Intern Med 2006; 45:897-901.

  31. Raissian Y, Nasr SH, Larsen CP, Colvin RB, Smyrk TC, Takahashi N, et al. Diagnosis of IgG4 related tubulo-interstitial nephritis. J Am Soc Nephrol 2011; 22:1343-1352.

  32. Deshpande V, Zen Y, Chan J, Yi Eunhee, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; May:1-12.

  33. Okazaki K, Uchida K, Miyoshi H, et al. Recent concepts of autoimmune pancreatitis and IgG4 related disease. Clin Rev Allergy Immunol 2011; 41:126-138.

  34. Okazaki K, Uchida K, Koyabu M, Miyoshi H, Ikeura T, Takaoka M, et al. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4 related disease. J Gastroenterol 2011; 46:277-288.

  35. Carruthers M, Stone J, Khosroshahi. The latest on IgG4-RD: a rapidly emerging disease. Curr Opin Rheumatol 2012; 24:60-69.

  36. Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol 2011; 23:108-13.

  37. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58:1504-1507.

  38. Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N, et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005; 30:31-39.

  39. Kamisawa T, Chung JB, Irie H, Nishino T, Ueki T, Takase M, et al. Japan-Korea Symposium on Autoimmune Pancreatitis (KOKURA 2007). Pancreas 2007; 35:281-284.

  40. Ko SB, Mizuno N, Yatabe Y, Yoshikawa T, Ishiguro H, Yamamoto A, et al. Corticoisteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010; 138:1988-1996.

  41. Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45:471-477.

  42. Panala R, Chari ST. Corticosteroid treatment for auto immune pancreatitis. Gut 2009; 58:1438-1439.

  43. Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long-term prognosis of autoinmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56:1719-1724.

  44. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134:706-715.

  45. Kubota K, Lida H, Fujisawa T, Yoneda M, Inamori M, Abe Y, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoinmune pancreatitis. Gastrointest Endosc 2007; 66:1142-1151.

  46. Naitoh I, Nakazawa T, Ohara H, Sano H, Ando T, Hayashi K, et al. Autoimmune pancreatitis associated with various extrapancreatic lesions during a long-term clinical course successfully treated with azathioprine and corticosteroid maintenance therapy. Intern Med 2009; 48:2003-2007.

  47. Church Nl, Pereira SP, Deheragoda MG, Sandanayake N, Amin Z, Lees WR, et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007; 102:2471-2425.

  48. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772-1779.

  49. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62:1755-1762.

  50. Khosroshahi A, Stone J. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23:67-71.

  51. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH, et al. Rituximab for the treatment of IgG4-Related Disease Lessons From 10 Consecutive Patients. Medicine 2012; 91:57-66.

  52. Sato Y, Yoshino T. IgG4-Related Lymphadenopathy. Inter J Rheumatol 2012; 572539:1-8.

  53. Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14(25):3948-3955.

  54. Stone J, Zen Y, Deshpande V. IgG4-Related Disease. N Engl J Med 2012; 366:539-551.

  55. Shigemitsu H, Koss M. IgG4-related interstitial lung disease: a new and evolving concept. Curr Opin Pulm Med 2009; 15:513-516.

  56. Ryu J, Horie R, Sekiguchi H, Peikert T, Yi E. Spectrum of Disorders Associated with Elevated Serum IgG4 Levels Encountered in Clinical Practice. Inter J Rheumatol 2012; 232960:1-6.

  57. Ebbo M, Daniel L, Pavic M, Seve P, et al. IgG4-Related Systemic Disease Features and Treatment Response in a French Cohort: Results of a Multicenter Registry. Medicine 2012; 91:49-56.




2020     |     www.medigraphic.com